G&A at other companies
Other financials
Where this comes from
Reported directly by Relmada Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:GeneralAndAdministrativeExpense.
The official record: Relmada Therapeutics, Inc.’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →
Ask your AI about Relmada Therapeutics, Inc.'s g&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Relmada Therapeutics, Inc.'s G&A?
- Relmada Therapeutics, Inc. (RLMD) reported G&A of $11.37M in Q1 2026.
- How has Relmada Therapeutics, Inc.'s G&A changed year-over-year?
- Relmada Therapeutics, Inc.'s G&A increased by 81.5% year-over-year, from $6.27M to $11.37M.
- What is the long-term trend for Relmada Therapeutics, Inc.'s G&A?
- Over 4 years (2021 to 2025), Relmada Therapeutics, Inc.'s G&A has grown at a -2.1% compound annual growth rate (CAGR), from $35.08M to $32.22M.
- What does G&A mean?
- Overhead costs not directly tied to production or sales — corporate management, legal, accounting, office rent, insurance, and other administrative functions.